Announcements Trials
Browse Landscape

Phase

Phase 3 36Phase 2 31Phase NA 3Phase 1 3Phase 1/2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 1Hodgkin Disease 1

Interventions

Rituximab 169Cyclophosphamide 158fludarabine 76Lenalidomide 73Vincristine 70fludarabine phosphate 63Etoposide 59Doxorubicin 56Prednisone 54venetoclax 49Cytarabine 48Dexamethasone 43Filgrastim 39Peripheral Blood Stem Cell Transplantation 38Methotrexate 38Bendamustine Hydrochloride 38ibrutinib 37obinutuzumab 36Gemcitabine 31pembrolizumab 27Melphalan 27Bortezomib 27Alemtuzumab 25Radiotherapy 23Nivolumab 21Carboplatin 21Tacrolimus 20Granulocyte Colony-Stimulating Factor 20Busulfan 20Whole-Body Irradiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Bleomycin × Lymphoid × Clear all
NCT03033914 2026-02-17

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
82 enrolled
Lymphoid

Hodgkin Disease

NCT00032149 2013-09-20

Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
30 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡